Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 129 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lactobacillus casei Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome

NCT01545037
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®, Placebo
Dietary Supplement · Other
Lead sponsor
Bio-K Plus International Inc.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
3
States / cities
Garden Grove, California • San Francisco, California • Westlake Village, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BCG Vaccination Delivered Intradermally, Orally and by Combined Routes

NCT00396370
View directory record Official record
Conditions
Tuberculosis
Interventions
BCG strain Connaught, BCG strain Danish, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 17, 2026, 2:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

NCT05316155
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
Erdafitinib Intravesical Delivery System
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 2:09 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

NCT03711032
View directory record Official record
Conditions
High-risk Non-muscle Invasive Bladder Cancer
Interventions
Pembrolizumab, BCG
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2034
U.S. locations
44
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 17, 2026, 2:09 PM EDT
Terminated Phase 2 Interventional Results available

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

NCT03719300
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
inodiftagene vixteplasmid
Drug
Lead sponsor
Anchiano Therapeutics Israel Ltd.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
48
States / cities
Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 17, 2026, 2:09 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Food Trial to Evaluate the Kinetics of the Medical Foods SBD111 and SBD121 Persistence in Healthy Adults

NCT06614166
View directory record Official record
Conditions
Product Persistence in GI Tract, Kinetics, Rheumatoid Arthritis (RA), Bone Density
Interventions
SBD111 Probiotic Medical Food, SBD121 Probiotic Medical Food
Other
Lead sponsor
Solarea Bio, Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety Evaluation of a Diet and Nutritional Supplementation Program- Purify 2.0

NCT03685552
View directory record Official record
Conditions
Gastrointestinal Symptoms
Interventions
Prog: Purify-2
Other
Lead sponsor
Nature's Sunshine Products, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lehi, Utah
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Not applicable Interventional

Engineering Gut Microbiome to Target Breast Cancer

NCT03358511
View directory record Official record
Conditions
Breast Cancer
Interventions
Probiotic
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 17, 2026, 2:09 PM EDT
Not listed Not applicable Interventional

Probiotics Pilot Project

NCT04247854
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Bacillus subtilis probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 17, 2026, 2:09 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

NCT07559175
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
Interventions
NHS7108, Zenpep®
Drug
Lead sponsor
Aimmune Nestlé Health Science US R&D, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 2:09 PM EDT
Active, not recruiting Phase 2 Interventional

Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes

NCT05180591
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes type1, Autoimmune Diabetes
Interventions
Bacillus Calmette-Guérin, Saline Injection
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 17, 2026, 2:09 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
TAR-200, Mitomycin C, Gemcitabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
29
States / cities
Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 2:09 PM EDT
Terminated Phase 3 Interventional Results available

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

NCT04149574
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
nivolumab, Placebo, Bacillus Calmette-Guérin (BCG)
Drug · Other · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

BCG Vaccine for Health Care Workers as Defense Against COVID 19

NCT04348370
View directory record Official record
Conditions
Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere
Interventions
BCG Vaccine, Placebo Vaccine
Biological
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 75 Years
Enrollment
659 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Bryan, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 17, 2026, 2:09 PM EDT
Available No phase listed Expanded access

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

NCT06443944
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Urologic Cancer, Bladder Cancer
Interventions
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
Drug · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
27
States / cities
Gilbert, Arizona • Bakersfield, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 17, 2026, 2:09 PM EDT
Active, not recruiting Phase 3 Interventional

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

NCT05943106
View directory record Official record
Conditions
Non-Muscle- Invasive Bladder Cancer
Interventions
Durvalumab, BCG
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 2 Interventional

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

NCT04387461
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer
Interventions
CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside
Biological · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
La Jolla, California • Orange, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Establishing Effects of Bacillus Clausii Probiotic Consumption on Gastrointestinal Health and Inflammation

NCT07618026
View directory record Official record
Conditions
Gastrointestinal Health
Interventions
Bacillus (Shouchella) clausii CSI08, Placebo
Dietary Supplement · Other
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 17, 2026, 2:09 PM EDT
Available No phase listed Expanded access

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

NCT06810141
View directory record Official record
Conditions
NMIBC
Interventions
rMBCG
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 100 Years
U.S. locations
66
States / cities
Homewood, Alabama • Mobile, Alabama • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 17, 2026, 2:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

NCT04179162
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer (NMIBC)
Interventions
Bacillus Calmette-Guérin (BCG), Gemcitabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
8
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 17, 2026, 2:09 PM EDT
Withdrawn Phase 1 Interventional

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

NCT04109092
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
E7766
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Gilbert, Arizona • Los Angeles, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 17, 2026, 2:09 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes

NCT07388264
View directory record Official record
Conditions
Gastrointestinal Symptoms, Constipation, Gut Health, Gastrointestinal Function
Interventions
Weizmannia (Bacillus) coagulans JBI-YZ6.3, Placebo
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Measuring the Influence of Kefir on Children's Stools on Antibiotics (MILK)

NCT00481507
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Kefir, Placebo
Other
Lead sponsor
Georgetown University
Other
Eligibility
1 Year to 5 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 17, 2026, 2:09 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

NCT02901548
View directory record Official record
Conditions
Carcinoma in Situ of Bladder, Bladder Cancer
Interventions
Durvalumab, Cystoscopy with Biopsy
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Miami Beach, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 17, 2026, 2:09 PM EDT